Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Promising Phase II Data For Sanofi’s Hemlibra Rival Fitusiran

Gene Therapy Also Approaching Market

Executive Summary

Sanofi has unveiled encouraging Phase II data for fitusiran, a novel RNA-based hemophilia therapy which could eventually challenge Roche’s blockbuster Hemlibra.

You may also be interested in...



No Looking Back For Sanofi In R&D Turnaround Quest

Sanofi's R&D operation has shaken the dust of diabetes off its feet with an update on its ambitious pipeline plans at an R&D day event.

BioMarin’s Hemophilia Gene Therapy Still Works After Four Years, But Effects Tail Off

Latest results show a show decline in effects, but still offers freedom from injections with almost no bleeds recorded in 13 patients.

First COVID-19 Trial Success For Roche’s Actemra, But No Sign It Saves Lives

A composite endpoint conceals Actemra’s lack of mortality benefit – while life-saving dexamethasone gets EMA endorsement.

Topics

Related Companies

UsernamePublicRestriction

Register

ID001014

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel